Cervicovaginal safety of the formulated, biguanide-based human immunodeficiency virus type 1 (HIV-1) inhibitor NB325 in a murine model
- PMID: 22131821
- PMCID: PMC3202145
- DOI: 10.1155/2011/941061
Cervicovaginal safety of the formulated, biguanide-based human immunodeficiency virus type 1 (HIV-1) inhibitor NB325 in a murine model
Abstract
Vaginal microbicides that reduce or eliminate the risk of HIV-1 sexual transmission must do so safely without adversely affecting the integrity of the cervicovaginal epithelium. The present studies were performed to assess the safety of the biguanide-based antiviral compound NB325 in a formulation suitable for topical application. Experiments were performed using a mouse model of cervicovaginal microbicide application, which was previously shown to be predictive of topical agent toxicity revealed in microbicide clinical trials. Mice were exposed vaginally to unformulated NB325 or NB325 formulated in the hydroxyethyl cellulose "universal placebo." Following exposures to formulated 1% NB325 for 10 min to 24 h, the vaginal and cervical epithelia were generally intact, although some areas of minimal vaginal epithelial damage were noted. Although formulated NB325 appeared generally safe for application in these studies, the low but observable level of toxicity suggests the need for improvements in the compound and/or formulation.
Figures
References
-
- Joint United Nations Programme on HIV/AIDS (UNAIDS) Global report: UNAIDS report on the global AIDS epidemic 2010. 2010, http://www.unaids.org/globalreport/Global_report.htm.
-
- Balzarini J, Van Damme L. Microbicide drug candidates to prevent HIV infection. Lancet. 2007;369(9563):787–797. - PubMed
-
- Ramjee G. Microbicide research: current and future directions. Current Opinion in HIV and AIDS. 2010;5(4):316–321. - PubMed
-
- Nuttall J. Microbicides in the prevention of HIV infection: current status and future directions. Drugs. 2010;70(10):1231–1243. - PubMed
-
- Zydowsky TM. Microbicides: chemistry, structure, and strategy. Current Opinion in HIV and AIDS. 2008;3(5):548–553. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
